

Walter Mier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4263685/publications.pdf>

Version: 2024-02-01

133
papers

10,629
citations

44042

48
h-index

33869

99
g-index

141
all docs

141
docs citations

141
times ranked

9117
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics. <i>Pharmaceuticals</i> , 2022, 15, 159.	1.7	2
2	[¹⁵³ Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3011-3013.	3.3	60
3	Virus-Derived Peptides for Hepatic Enzyme Delivery. <i>Molecular Pharmaceutics</i> , 2021, 18, 2004-2014.	2.3	1
4	Mass Spectrometric Quantification of the Antimicrobial Peptide Pep19-2.5 with Stable Isotope Labeling and Acidic Hydrolysis. <i>Pharmaceutics</i> , 2021, 13, 1342.	2.0	0
5	Trends in liposomal nanocarrier strategies for the oral delivery of biologics. <i>Nanomedicine</i> , 2021, 16, 1813-1832.	1.7	7
6	¹⁸ F-labeled tracers targeting fibroblast activation protein. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 26.	1.8	38
7	Overcoming the Mucosal Barrier: Tetraether Lipid- ϵ -Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin. <i>Advanced Therapeutics</i> , 2021, 4, 2000247.	1.6	16
8	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 70-79.	2.8	23
9	Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria. <i>Canadian Journal of Microbiology</i> , 2020, 66, 11-16.	0.8	75
10	Response Prediction of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39
11	Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102132.	1.7	38
12	Innenrücktitelbild: Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden (Angew. Chem. 23/2020). <i>Angewandte Chemie</i> , 2020, 132, 9277-9277.	1.6	0
13	Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19-4LF). <i>Antibiotics</i> , 2020, 9, 844.	1.5	12
14	Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci. <i>Pharmaceuticals</i> , 2020, 13, 110.	1.7	15
15	Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 8823-8827.	7.2	56
16	Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden. <i>Angewandte Chemie</i> , 2020, 132, 8908-8912.	1.6	0
17	Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. <i>Journal of Controlled Release</i> , 2020, 322, 200-208.	4.8	30
18	Design and Development of ^{99m} Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸ Re Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1507-1513.	2.8	110

#	ARTICLE	IF	CITATIONS
19	⁶⁸ Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 386-392.	2.8	468
20	Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 40-69.	5.0	88
21	Replacement of l-Amino Acids by d-Amino Acids in the Antimicrobial Peptide Ranalexin and Its Consequences for Antimicrobial Activity and Biodistribution. <i>Molecules</i> , 2019, 24, 2987.	1.7	18
22	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. <i>Mutagenesis</i> , 2019, 34, 239-244.	1.0	12
23	Preclinical evaluation of peptide-based radiotracers for integrin $\alpha_6\beta_1$ -positive pancreatic carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 309-318.	0.3	8
24	Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1421-1429.	2.8	281
25	⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 801-805.	2.8	874
26	PET/CT Imaging of NSCLC with a $\alpha_6\beta_1$ Integrin-Targeting Peptide. <i>Molecular Imaging and Biology</i> , 2019, 21, 973-983.	1.3	21
27	Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. <i>Onc Immunology</i> , 2019, 8, e1524694.	2.1	8
28	Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 82-93.	1.7	40
29	Development and dosimetry of ²⁰³ Pb/ ²¹² Pb-labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1081-1091.	3.3	77
30	Dosimetry Estimate and Initial Clinical Experience with ⁹⁰ Y-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2019, 60, 806-811.	2.8	27
31	Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. <i>ELife</i> , 2019, 8, .	2.8	20
32	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1179-1187.	3.3	26
33	Comparison of the RGD Motif-Containing $\alpha_6\beta_1$ Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1679-1685.	2.8	38
34	A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1423-1429.	2.8	453
35	Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1415-1422.	2.8	522
36	A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 52-62.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Intraindividual Comparison of ^{99m} Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m} Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	2.8	31
38	Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.	2.8	68
39	Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
40	Phenomenon of Endothelial Antibody Capture: Principles and Potential for Locoregional Targeting of Hepatic Tumors. <i>Hepatology</i> , 2018, 68, 1804-1816.	3.6	9
41	Strategies for the treatment of HBV/HDV. <i>European Journal of Pharmacology</i> , 2018, 833, 379-391.	1.7	16
42	Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. <i>Oncotarget</i> , 2018, 9, 29985-30004.	0.8	11
43	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 750-755.	2.8	105
44	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with ¹³¹ I-MIP-1095. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 950-959.	3.3	69
45	⁶⁸ Ga or ¹⁸ F for Prostate Cancer Imaging?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 687-688.	2.8	105
46	Diagnostic performance of ⁶⁸ Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
47	Identification of a Novel ITG α 6-Binding Peptide Using Protein Separation and Phage Display. <i>Clinical Cancer Research</i> , 2017, 23, 4170-4180.	3.2	37
48	⁶⁸ Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1943-1948.	2.8	81
49	A scavenger peptide prevents methylglyoxal induced pain in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 654-662.	1.8	30
50	A Polymer/Peptide Complex-Based Sensor Array That Discriminates Bacteria in Urine. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 15246-15251.	7.2	130
51	A Polymer/Peptide Complex-Based Sensor Array That Discriminates Bacteria in Urine. <i>Angewandte Chemie</i> , 2017, 129, 15448-15453.	1.6	15
52	Identification of Ligands and Translation to Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2017, 58, 27S-33S.	2.8	16
53	Oral delivery of vancomycin by tetraether lipid liposomes. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 108, 111-118.	1.9	69
54	Improving the Imaging Contrast of ⁶⁸ Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. <i>Bioconjugate Chemistry</i> , 2017, 28, 2485-2492.	1.8	40

#	ARTICLE	IF	CITATIONS
55	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	2.8	27
56	Integration of CT urography improves diagnostic confidence of ⁶⁸ Ga-PSMA-11 PET/CT in prostate cancer patients. <i>Cancer Imaging</i> , 2017, 17, 30.	1.2	8
57	Multicyclic Peptides as Scaffolds for the Development of Tumor Targeting Agents. <i>Current Medicinal Chemistry</i> , 2017, 24, 2141-2155.	1.2	11
58	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <i>Theranostics</i> , 2016, 6, 1085-1095.	4.6	60
59	A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 103, 159-166.	2.0	63
60	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. <i>International Journal of Pharmaceutics</i> , 2016, 512, 87-95.	2.6	33
61	Preclinical evaluation of a diabody-based ¹⁷⁷ Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. <i>Cancer Letters</i> , 2016, 381, 296-304.	3.2	3
62	Drug Conjugation Affects Pharmacokinetics and Specificity of Kidney-Targeted Peptide Carriers. <i>Bioconjugate Chemistry</i> , 2016, 27, 2441-2449.	1.8	21
63	A Slow Maturation Process Renders Hepatitis B Virus Infectious. <i>Cell Host and Microbe</i> , 2016, 20, 25-35.	5.1	50
64	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. <i>Journal of Translational Medicine</i> , 2016, 14, 99.	1.8	8
65	¹⁸ F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1929-1930.	3.3	81
66	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176.	2.8	475
67	Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. <i>Bioconjugate Chemistry</i> , 2016, 27, 1050-1057.	1.8	62
68	Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1761-1775.	2.9	150
69	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. <i>Gastroenterology</i> , 2016, 150, 513-525.e10.	0.6	78
70	High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a ¹⁷⁷ Lu-based CD22-specific radioimmunoconjugate and rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 489-498.	3.3	13
71	Advantages in functional imaging of the brain. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 249.	1.0	61
72	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	0.9	19

#	ARTICLE	IF	CITATIONS
73	Impaired uptake of conjugated bile acids and hepatitis b virus pres1 binding in na+ taurocholate cotransporting polypeptide knockout mice. <i>Hepatology</i> , 2015, 62, 207-219.	3.6	116
74	An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. <i>Cancer Letters</i> , 2015, 357, 364-373.	3.2	9
75	Cancer Stratification by Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4918-4946.	1.8	20
76	Generation of suppressive blood cells for control of allograft rejection. <i>Clinical Science</i> , 2015, 128, 593-607.	1.8	19
77	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920.	2.8	451
78	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	2.8	332
79	Radionuclides in drug development. <i>Drug Discovery Today</i> , 2015, 20, 198-208.	3.2	29
80	Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis. <i>PLoS ONE</i> , 2015, 10, e0133291.	1.1	9
81	Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs. <i>Molecules</i> , 2014, 19, 2135-2165.	1.7	48
82	Current Status in the Therapy of Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7500-7512.	1.8	34
83	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹ I-BA52. <i>Journal of Nuclear Medicine</i> , 2014, 55, 9-14.	2.8	48
84	Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13499-13504.	3.3	30
85	Is nano too big?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 4-6.	3.3	14
86	Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1280-1292.	3.3	319
87	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. <i>Clinical and Translational Imaging</i> , 2014, 2, 33-41.	1.1	1
88	Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. <i>Journal of Hepatology</i> , 2014, 60, 723-731.	1.8	217
89	Selective targeting of liver cancer with the endothelial marker CD146. <i>Oncotarget</i> , 2014, 5, 8614-8624.	0.8	15
90	Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 200-209.	0.9	11

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH) ₃ -Conjugates in Important Organs. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1327-1330.	2.8	24
92	A Disulfide-Constrained Miniprotein with Striking Tumor-Binding Specificity Developed by Ribosome Display. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 11760-11764.	7.2	11
93	Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. <i>Hepatology</i> , 2013, 58, 31-42.	3.6	113
94	PEGylation enables the specific tumor accumulation of a peptide identified by phage display. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 2706.	1.5	8
95	A Mild Method for Regioselective Labeling of Aromatics with Radioactive Iodine. <i>European Journal of Organic Chemistry</i> , 2013, 2013, 3970-3973.	1.2	10
96	Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. <i>Hepatology</i> , 2013, 58, 43-53.	3.6	102
97	Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer. <i>Molecular Pharmaceutics</i> , 2013, 10, 2230-2236.	2.3	6
98	Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX. <i>Molecular Imaging</i> , 2013, 12, 7290.2013.00066.	0.7	17
99	Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases. <i>Molecules</i> , 2013, 18, 3379-3409.	1.7	74
100	DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl. <i>PLoS ONE</i> , 2013, 8, e60350.	1.1	28
101	Acid-Mediated Prevention of Aspartimide Formation in Solid Phase Peptide Synthesis. <i>Organic Letters</i> , 2012, 14, 5218-5221.	2.4	55
102	DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA-peptide conjugates. <i>Tetrahedron Letters</i> , 2012, 53, 6810-6814.	0.7	7
103	Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumor-Targeting Miniproteins. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 13136-13139.	7.2	34
104	A dimerized urea-based inhibitor of the prostate-specific membrane antigen for ⁶⁸ Ga-PET imaging of prostate cancer. <i>EJNMMI Research</i> , 2012, 2, 23.	1.1	134
105	⁶⁸ Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. <i>Bioconjugate Chemistry</i> , 2012, 23, 688-697.	1.8	709
106	Engineering and Functionalization of the Disulfide-Constrained Miniprotein Min ₂₃ as a Scaffold for Diagnostic Application. <i>ChemMedChem</i> , 2012, 7, 237-247.	1.6	14
107	DNA Libraries for the Construction of Phage Libraries: Statistical and Structural Requirements and Synthetic Methods. <i>Molecules</i> , 2011, 16, 1625-1641.	1.7	22
108	Miniproteins as Phage Display-Scaffolds for Clinical Applications. <i>Molecules</i> , 2011, 16, 2467-2485.	1.7	31

#	ARTICLE	IF	CITATIONS
109	Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. <i>Endocrine-Related Cancer</i> , 2011, 18, 595-602.	1.6	79
110	⁶⁸ Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1397-1407.	3.3	50
111	Hot or not – the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. <i>Tetrahedron Letters</i> , 2010, 51, 6216-6219.	0.7	12
112	Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction. <i>Journal of Virology</i> , 2010, 84, 1989-2000.	1.5	201
113	Endoradiotherapy in cancer treatment – Basic concepts and future trends. <i>European Journal of Pharmacology</i> , 2009, 625, 55-62.	1.7	46
114	Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for ⁶⁸ Ga-labeled small recombinant antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1878-1886.	3.3	93
115	PAMAM Structure-Based Multifunctional Fluorescent Conjugates for Improved Fluorescent Labelling of Biomacromolecules. <i>Chemistry - A European Journal</i> , 2008, 14, 8116-8130.	1.7	35
116	Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2606-2616.	1.4	41
117	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. <i>Nature Biotechnology</i> , 2008, 26, 335-341.	9.4	369
118	Endoradiotherapy with Peptides - Status and Future Development. <i>Current Medicinal Chemistry</i> , 2008, 15, 219-234.	1.2	28
119	Radiolabeled Peptides and Proteins in Cancer Therapy. <i>Protein and Peptide Letters</i> , 2007, 14, 273-279.	0.4	25
120	Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1. <i>Journal of Nuclear Medicine</i> , 2007, 48, 965-972.	2.8	30
121	Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1545-1552.	2.8	17
122	Manual Solid-Phase Peptide Synthesis of Metallocene-Peptide Bioconjugates. <i>Journal of Chemical Education</i> , 2007, 84, 108.	1.1	60
123	Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2007, 10, 286s-297s.	0.9	4
124	Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. <i>Journal of Nuclear Medicine</i> , 2006, 47, 981-8.	2.8	27
125	Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160. <i>Clinical Cancer Research</i> , 2005, 11, 6705-6712.	3.2	71
126	Conjugation of DOTA Using Isolated Phenolic Active Esters: The Labeling and Biodistribution of Albumin as Blood Pool Marker. <i>Bioconjugate Chemistry</i> , 2005, 16, 237-240.	1.8	57

#	ARTICLE	IF	CITATIONS
127	A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. <i>Clinical Cancer Research</i> , 2005, 11, 139-46.	3.2	61
128	Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. <i>Journal of Nuclear Medicine</i> , 2005, 46, 782-5.	2.8	24
129	Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. <i>Tetrahedron Letters</i> , 2004, 45, 5453-5455.	0.7	14
130	Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. <i>Nuclear Medicine and Biology</i> , 2004, 31, 21-30.	0.3	19
131	Fluorescent Somatostatin Receptor Probes for the Intraoperative Detection of Tumor Tissue with Long-Wavelength Visible Light. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 2543-2552.	1.4	17
132	A general method for functionalising both the C- and N-terminals of Tyr 3 -octreotate. <i>Tetrahedron Letters</i> , 2002, 43, 5021-5024.	0.7	17
133	DNA adduct formation by the ubiquitous environmental contaminant 3-nitrobenzanthrone in rats determined by ³² P-postlabeling. <i>International Journal of Cancer</i> , 2001, 93, 450-454.	2.3	75